Kent and Medway
Joint Medicines Formulary

Drug Safety Update

 July 2020: Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection

April 2016: Aflibercept (Zaltrap▼): minimising the risk of osteonecrosis of the jaw

NICE Guidance (see also drug specific links below)

 NG82: Age-related macular degeneration, January 2018.

These drugs are for specialist use only and should be used in accordance with NICE guidance.

Aflibercept

Ophthalmology Initiation High Cost Drug Go to NICE for more information and guidance. Go to the EMC website for more information and guidance. Go to the Blueteq website for more information and guidance.

Faricimab

Ophthalmology Initiation High Cost Drug Go to NICE for more information and guidance. Go to the EMC website for more information and guidance. Go to the Blueteq website for more information and guidance.

Ranibizumab

Ophthalmology Initiation High Cost Drug Go to NICE for more information and guidance. Go to the EMC website for more information and guidance. Go to the Blueteq website for more information and guidance.
  • On Formulary Preferred
  • On Formulary Second Line
  • On Formulary Third Line
  • Specialist Initiation
  • Secondary Care Only
  • Not Approved for Formulary